United States (US) Investigational New Drug CDMO Market (2025-2031) | Growth, Segmentation, Industry, Analysis, Outlook, Competitive Landscape, Forecast, Companies, Trends, Share, Size & Revenue, Value

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) Investigational New Drug CDMO Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) Investigational New Drug CDMO Market - Industry Life Cycle

3.4 United States (US) Investigational New Drug CDMO Market - Porter's Five Forces

3.5 United States (US) Investigational New Drug CDMO Market Revenues & Volume Share, By Product, 2021 & 2031F

3.6 United States (US) Investigational New Drug CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F

3.7 United States (US) Investigational New Drug CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increase in RD investments in pharmaceutical and biotechnology industries

4.2.2 Growing demand for outsourcing drug development and manufacturing services

4.2.3 Technological advancements in drug development processes

4.3 Market Restraints

4.3.1 Stringent regulatory requirements and compliance standards

4.3.2 High initial investments required for setting up investigational new drug manufacturing facilities

4.3.3 Intellectual property concerns and confidentiality issues

6.1 United States (US) Investigational New Drug CDMO Market, By Product

6.1.1 Overview and Analysis

6.1.2 United States (US) Investigational New Drug CDMO Market Revenues & Volume, By Product, 2021- 2031F

6.1.3 United States (US) Investigational New Drug CDMO Market Revenues & Volume, By Small Molecule, 2021- 2031F

6.1.4 United States (US) Investigational New Drug CDMO Market Revenues & Volume, By Large Molecule, 2021- 2031F

6.2 United States (US) Investigational New Drug CDMO Market, By Service

6.2.1 Overview and Analysis

6.2.2 United States (US) Investigational New Drug CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F

6.2.3 United States (US) Investigational New Drug CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F

6.3 United States (US) Investigational New Drug CDMO Market, By End-user

6.3.1 Overview and Analysis

6.3.2 United States (US) Investigational New Drug CDMO Market Revenues & Volume, By Pharmaceutical Companies, 2021- 2031F

6.3.3 United States (US) Investigational New Drug CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F

6.3.4 United States (US) Investigational New Drug CDMO Market Revenues & Volume, By Others, 2021- 2031F

7.1 United States (US) Investigational New Drug CDMO Market Export to Major Countries

7.2 United States (US) Investigational New Drug CDMO Market Imports from Major Countries

8.1 Average project turnaround time for investigational new drug development

8.2 Number of successful regulatory approvals for investigational new drugs

8.3 Percentage of client retention rate for investigational new drug CDMO services

9.1 United States (US) Investigational New Drug CDMO Market Opportunity Assessment, By Product, 2021 & 2031F

9.2 United States (US) Investigational New Drug CDMO Market Opportunity Assessment, By Service, 2021 & 2031F

9.3 United States (US) Investigational New Drug CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F

10.1 United States (US) Investigational New Drug CDMO Market Revenue Share, By Companies, 2024

10.2 United States (US) Investigational New Drug CDMO Market Competitive Benchmarking, By Operating and Technical Parameters